InMed terminates interim CFO Brenda Edwards; promotes Sarah Li to VP Accounting and Controller

InMed Pharmaceuticals Inc.

Brenda Edwards' consulting agreement terminated effective Nov 20, 2022; she served as interim CFO since April 2022.
Sarah Li promoted to VP of Accounting and Controller and Principal Accounting Officer; she was Controller since Jan 2020.
Company in discussions to engage new interim financial leadership (CFO) consulting services.
Press release issued Nov 17, 2022 providing management change update.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Sarah Li

Vice President of Accounting and Controller and Principal Accounting Officer

INM · InMed Pharmaceuticals Inc.

Filed: November 17, 2022, 6:59 PM ET

The Company’s Controller, Sarah Li, has been promoted to Vice President of Accounting and Controller and Principal Accounting Officer.

Departed (interim)

Brenda Edwards

Interim Chief Financial Officer

INM · InMed Pharmaceuticals Inc.

Effective: 2022-11-20
Filed: November 17, 2022, 6:59 PM ET

On November 14, 2022, the Company terminated the Consulting Agreement for Brenda Edwards effective November 20, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sarah Li changed role as Vice President of Accounting and Controller and Principal Accounting Officer at InMed Pharmaceuticals Inc..

Action: promoted
Role: Vice President of Accounting and Controller and Principal Accounting Officer

Exact text from the filing

The Company’s Controller, Sarah Li, has been promoted to Vice President of Accounting and Controller and Principal Accounting Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brenda Edwards was terminated as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..

Action: terminated
Role: Interim Chief Financial Officer

Exact text from the filing

On November 14, 2022, the Company terminated the Consulting Agreement for Brenda Edwards effective November 20, 2022.

View on SEC.gov

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-073492

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.